Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic and Advanced Phase Myelofibrosis
Open Access
- 1 December 2016
- journal article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 22 (12) , 2180-2186
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosisBlood, 2014
- Dynamic of Bone Marrow Fibrosis Regression Predicts Survival after Allogeneic Stem Cell Transplantation for MyelofibrosisTransplantation and Cellular Therapy, 2014
- Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasmCurrent Opinion in Hematology, 2014
- Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor RuxolitinibCurrent Medicinal Chemistry, 2012
- Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitorsBlood, 2012
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for MyelofibrosisNew England Journal of Medicine, 2012
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for MyelofibrosisNew England Journal of Medicine, 2012
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion StatusJournal of Clinical Oncology, 2011
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)Blood, 2010
- New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and TreatmentBlood, 2009